Skip to main content
Top
Published in: Journal of Inflammation 1/2011

Open Access 01-12-2011 | Research

Arthrogenicity of type II collagen monoclonal antibodies associated with complement activation and antigen affinity

Authors: Thongchai Koobkokkruad, Tatsuya Kadotani, Pilaiwanwadee Hutamekalin, Nobuaki Mizutani, Shin Yoshino

Published in: Journal of Inflammation | Issue 1/2011

Login to get access

Abstract

Background

The collagen antibody-induced arthritis (CAIA) model, which employs a cocktail of monoclonal antibodies (mAbs) to type II collagen (CII), has been widely used for studying the pathogenesis of autoimmune arthritis. In this model, not all mAbs to CII are capable of inducing arthritis because one of the initial events is the formation of collagen-antibody immune complexes on the cartilage surface or in the synovium, and subsequent activation of the complement by the complexes induces arthritis, suggesting that a combination of mAbs showing strong ability to bind mouse CII and activate the complement may effectively induce arthritis in mice. In the present study, we examined the relationship between the induction of arthritis by the combination of IgG2a (CII-6 and C2A-12), IgG2b (CII-3, C2B-14 and C2B-16) and IgM (CM-5) subclones of monoclonal antibodies (mAb) of anti-bovine or chicken CII and the ability of mAbs to activate complement and bind mouse CII.

Methods

DBA/1J mice were injected with several combinations of mAbs followed by lipopolysaccharide. Furthermore, the ability of mAbs to activate the complement and bind mouse CII was examined by ELISA.

Results

First, DBA/1J mice were injected with the combined 4 mAbs (CII-3, CII-6, C2B-14, and CM-5) followed by lipopolysaccharide, resulting in moderate arthritis. Excluding one of the mAbs, i.e., using only CII-3, CII-6, and C2B-14, induced greater inflammation of the joints. Next, adding C2A-12 but not C2B-16 to these 3 mAbs produced more severe arthritis. A combination of five clones, consisting of all 5 mAbs, was less effective. Histologically, mice given the newly developed 4-clone cocktail had marked proliferation of synovial tissues, massive infiltration by inflammatory cells, and severe destruction of cartilage and bone. Furthermore, 4 of the 6 clones (CII-3, CII-6, C2B-14, and C2A-12) showed not only a strong cross-reaction with mouse CII but also marked activation of the complement in vitro.

Conclusion

The combination of 4 mAbs showing strong abilities to activate the complement and bind mouse CII effectively induced arthritis in DBA/1J mice. This in vitro system may be useful for the selection of mAbs associated with the development of arthritis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cho YG, Cho ML, Min SY, Kim HY: Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun Rev. 2007, 7: 65-70. 10.1016/j.autrev.2007.08.001.PubMedCrossRef Cho YG, Cho ML, Min SY, Kim HY: Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun Rev. 2007, 7: 65-70. 10.1016/j.autrev.2007.08.001.PubMedCrossRef
2.
go back to reference Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B: Immunisation against heterologous type II collagen induces arthritis in mice. Nature. 1980, 283: 666-668. 10.1038/283666a0.PubMedCrossRef Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B: Immunisation against heterologous type II collagen induces arthritis in mice. Nature. 1980, 283: 666-668. 10.1038/283666a0.PubMedCrossRef
3.
go back to reference Stuart JM, Cremer MA, Townes AS, Kang AH: Type II collagen-induced arthritis in rats: passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J Exp Med. 1982, 155: 1-16. 10.1084/jem.155.1.1.PubMedCrossRef Stuart JM, Cremer MA, Townes AS, Kang AH: Type II collagen-induced arthritis in rats: passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J Exp Med. 1982, 155: 1-16. 10.1084/jem.155.1.1.PubMedCrossRef
4.
go back to reference Trentham DE: Collagen arthritis as a relevent model for rheumatoid arthritis: evidence pro and con. Arthritis Rheum. 1982, 25: 911-916. 10.1002/art.1780250801.PubMedCrossRef Trentham DE: Collagen arthritis as a relevent model for rheumatoid arthritis: evidence pro and con. Arthritis Rheum. 1982, 25: 911-916. 10.1002/art.1780250801.PubMedCrossRef
5.
go back to reference Myers LK, Rosloniec EF, Cremer MA, Kang AH: Collagen-induced arthritis, an animal model of autoimmunity. Life Sci. 1997, 61: 1861-1878. 10.1016/S0024-3205(97)00480-3.PubMedCrossRef Myers LK, Rosloniec EF, Cremer MA, Kang AH: Collagen-induced arthritis, an animal model of autoimmunity. Life Sci. 1997, 61: 1861-1878. 10.1016/S0024-3205(97)00480-3.PubMedCrossRef
6.
go back to reference Kagari T, Tanaka D, Doi H, Shimozato T: Essential role of Fc gamma receptors in anti-type II collagen antibody-induced arthritis. J Immunol. 2003, 170: 4318-4324.PubMedCrossRef Kagari T, Tanaka D, Doi H, Shimozato T: Essential role of Fc gamma receptors in anti-type II collagen antibody-induced arthritis. J Immunol. 2003, 170: 4318-4324.PubMedCrossRef
7.
go back to reference Hietala MA, Nandakumar KS, Persson L, Fahlen S, Holmdahl R, Pekna M: Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis. Eur J Immunol. 2004, 34: 1208-1216. 10.1002/eji.200424895.PubMedCrossRef Hietala MA, Nandakumar KS, Persson L, Fahlen S, Holmdahl R, Pekna M: Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis. Eur J Immunol. 2004, 34: 1208-1216. 10.1002/eji.200424895.PubMedCrossRef
8.
go back to reference Neumann E, Barnum SR, Tarner IH, Echols J, Fleck M, Judex M, Kullmann F, Mountz JD, Schölmerich J, Gay S, Müller-Ladner U: Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum. 2002, 46: 934-945. 10.1002/art.10183.PubMedCrossRef Neumann E, Barnum SR, Tarner IH, Echols J, Fleck M, Judex M, Kullmann F, Mountz JD, Schölmerich J, Gay S, Müller-Ladner U: Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum. 2002, 46: 934-945. 10.1002/art.10183.PubMedCrossRef
9.
go back to reference Kunh KA, Cozine CL, Tomooka B, Robinson WH, Holers VM: Complement receptor CR2/CR1 deficiency protects mice from collagen-induced arthritis and associates with reduced autoantibodies to type II collage and citrullinated antigens. Mol Immunol. 2008, 45: 2808-2819. 10.1016/j.molimm.2008.01.036.CrossRef Kunh KA, Cozine CL, Tomooka B, Robinson WH, Holers VM: Complement receptor CR2/CR1 deficiency protects mice from collagen-induced arthritis and associates with reduced autoantibodies to type II collage and citrullinated antigens. Mol Immunol. 2008, 45: 2808-2819. 10.1016/j.molimm.2008.01.036.CrossRef
10.
go back to reference Okroj M, Heinegård D, Holmdahl R, Blom AM: Rheumatoid arthritis and the complement system. Annals Med. 2007, 39: 517-530. 10.1080/07853890701477546.CrossRef Okroj M, Heinegård D, Holmdahl R, Blom AM: Rheumatoid arthritis and the complement system. Annals Med. 2007, 39: 517-530. 10.1080/07853890701477546.CrossRef
11.
go back to reference Song H, Qiao F, Atkinson C, Holers VM, Tomlinson S: A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol. 2007, 179: 7860-7867.PubMedCrossRef Song H, Qiao F, Atkinson C, Holers VM, Tomlinson S: A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol. 2007, 179: 7860-7867.PubMedCrossRef
12.
go back to reference Banda NK, Takahashi K, Wood AK, Holers VM, Arend WP: Pathogenic complement activation in collagen antibody induced arthritis in mice requires amplification by the alternative pathway. J Immunol. 2007, 179: 4101-4109.PubMedCrossRef Banda NK, Takahashi K, Wood AK, Holers VM, Arend WP: Pathogenic complement activation in collagen antibody induced arthritis in mice requires amplification by the alternative pathway. J Immunol. 2007, 179: 4101-4109.PubMedCrossRef
13.
go back to reference Banda NK, Levitt B, Wood AK, Takahashi K, Stahl GL, Holers VM, Arend WP: Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro. Clin Exp Immunol. 2009, 159: 100-108.PubMedCrossRef Banda NK, Levitt B, Wood AK, Takahashi K, Stahl GL, Holers VM, Arend WP: Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro. Clin Exp Immunol. 2009, 159: 100-108.PubMedCrossRef
14.
go back to reference Wouters D, Voskuyl AE, Molenaar ETH, Dijkmans BAC, Hack CE: Evaluation of classical complement pathway activation in rheumatoid arthritis. Arthristis Rheum. 2006, 54: 1143-1150. 10.1002/art.21729.CrossRef Wouters D, Voskuyl AE, Molenaar ETH, Dijkmans BAC, Hack CE: Evaluation of classical complement pathway activation in rheumatoid arthritis. Arthristis Rheum. 2006, 54: 1143-1150. 10.1002/art.21729.CrossRef
15.
go back to reference Stuart JM, Dixon FJ: Serum transfer of collagen-induced arthritis in mice. J Exp Med. 1983, 158: 378-392. 10.1084/jem.158.2.378.PubMedCrossRef Stuart JM, Dixon FJ: Serum transfer of collagen-induced arthritis in mice. J Exp Med. 1983, 158: 378-392. 10.1084/jem.158.2.378.PubMedCrossRef
16.
go back to reference Terato K, Hasty KA, Reife RA, Cremer MA, Kang AH, Stuart JM: Induction of arthritis with monoclonal antibodies to collagen. J Immunol. 1992, 148: 2103-2108.PubMed Terato K, Hasty KA, Reife RA, Cremer MA, Kang AH, Stuart JM: Induction of arthritis with monoclonal antibodies to collagen. J Immunol. 1992, 148: 2103-2108.PubMed
17.
go back to reference Nandakumar KS, Holmdahl R: Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. J Immunol Methods. 2005, 304: 126-136. 10.1016/j.jim.2005.06.017.PubMedCrossRef Nandakumar KS, Holmdahl R: Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. J Immunol Methods. 2005, 304: 126-136. 10.1016/j.jim.2005.06.017.PubMedCrossRef
18.
go back to reference Hutamekalin P, Saito T, Yamaki K, Mizutani N, Brand DD, Waritani T, Terato K, Yoshino S: Collagen antibody-induced arthritis in mice: Development of a new arthritogenic 5-clone cocktail of monoclonal anti-type II collagen antibodies. J Immunol Methods. 2009, 343: 49-55. 10.1016/j.jim.2009.01.009.PubMedCrossRef Hutamekalin P, Saito T, Yamaki K, Mizutani N, Brand DD, Waritani T, Terato K, Yoshino S: Collagen antibody-induced arthritis in mice: Development of a new arthritogenic 5-clone cocktail of monoclonal anti-type II collagen antibodies. J Immunol Methods. 2009, 343: 49-55. 10.1016/j.jim.2009.01.009.PubMedCrossRef
19.
go back to reference Terato K, Harper DS, Griffiths MM, Hasty DL, Ye XJ, Cremer MA, Seyer JM: Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity. 1995, 22: 137-147. 10.3109/08916939508995311.PubMedCrossRef Terato K, Harper DS, Griffiths MM, Hasty DL, Ye XJ, Cremer MA, Seyer JM: Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity. 1995, 22: 137-147. 10.3109/08916939508995311.PubMedCrossRef
20.
go back to reference Yoshino S, Ohsawa M: The role of lipopolysaccharide injected systemically in the reactivation of collagen-induce arthritis in mice. British J Pharmaco. 2000, 129: 1309-1314. 10.1038/sj.bjp.0703166.CrossRef Yoshino S, Ohsawa M: The role of lipopolysaccharide injected systemically in the reactivation of collagen-induce arthritis in mice. British J Pharmaco. 2000, 129: 1309-1314. 10.1038/sj.bjp.0703166.CrossRef
21.
go back to reference Cremer MA, Terato K, Watson WC, Griffiths MM, Townes AS, Kang AH: Collagen-induced arthritis in rats. Examination of the epitope specificities of circulating and cartilage-bound antibodies produced by outbred and inbred rats using cyanogen bromide-derived peptides purified from heterologous and homologous type II collagens. J Immunol. 1992, 149: 1045-1053.PubMed Cremer MA, Terato K, Watson WC, Griffiths MM, Townes AS, Kang AH: Collagen-induced arthritis in rats. Examination of the epitope specificities of circulating and cartilage-bound antibodies produced by outbred and inbred rats using cyanogen bromide-derived peptides purified from heterologous and homologous type II collagens. J Immunol. 1992, 149: 1045-1053.PubMed
22.
go back to reference Watson WC, Townes AS: Genetic susceptibility to murine collagen II autoimmune arthritis. Proposed relationship to the IgG2 autoantibody subclass response, complement C5, major histocompatability complex (MHC) and non MHC loci. J Exp Med. 1985, 162: 1878-1891. 10.1084/jem.162.6.1878.PubMedCrossRef Watson WC, Townes AS: Genetic susceptibility to murine collagen II autoimmune arthritis. Proposed relationship to the IgG2 autoantibody subclass response, complement C5, major histocompatability complex (MHC) and non MHC loci. J Exp Med. 1985, 162: 1878-1891. 10.1084/jem.162.6.1878.PubMedCrossRef
23.
go back to reference Nandakumar KS, Andrén M, Martinsson P, Bajtner E, Hellstrom S, Holmdahl R, Kleinau S: Induction of arthritis by single monoclonal IgG anti-collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory FcγRIIB. Eur J Immunol. 2003, 33: 2269-2277. 10.1002/eji.200323810.PubMedCrossRef Nandakumar KS, Andrén M, Martinsson P, Bajtner E, Hellstrom S, Holmdahl R, Kleinau S: Induction of arthritis by single monoclonal IgG anti-collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory FcγRIIB. Eur J Immunol. 2003, 33: 2269-2277. 10.1002/eji.200323810.PubMedCrossRef
24.
go back to reference Hepburn AL, Mason JC, Wang S, Shepherd CJ, Florey O, Haskard DO, Davies KA: Both Fcγ and complement receptors mediate transfer of immune complexes from erythrocytes to human macrophages under physiological flow conditions in vitro. Clin Exp Immunol. 2006, 146: 133-145. 10.1111/j.1365-2249.2006.03174.x.PubMedPubMedCentralCrossRef Hepburn AL, Mason JC, Wang S, Shepherd CJ, Florey O, Haskard DO, Davies KA: Both Fcγ and complement receptors mediate transfer of immune complexes from erythrocytes to human macrophages under physiological flow conditions in vitro. Clin Exp Immunol. 2006, 146: 133-145. 10.1111/j.1365-2249.2006.03174.x.PubMedPubMedCentralCrossRef
Metadata
Title
Arthrogenicity of type II collagen monoclonal antibodies associated with complement activation and antigen affinity
Authors
Thongchai Koobkokkruad
Tatsuya Kadotani
Pilaiwanwadee Hutamekalin
Nobuaki Mizutani
Shin Yoshino
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue 1/2011
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/1476-9255-8-31

Other articles of this Issue 1/2011

Journal of Inflammation 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.